The clinical utility of NSE for early SCLC screening was good, and Fagan's nomogram (Figure 9) showed that the post-test probability (PLR: 70%, NLR: 7%) differed substantially from the pretest probability (20%). Here, ENO2 is linked to small cell lung carcinoma.